Loading...
Docoh

Beam Therapeutics (BEAM)

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Company profile

Ticker
BEAM
Exchange
Website
CEO
John Evans
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Beam Therapeutics Securities Corporation • Guide Therapeutics, LLC ...

BEAM stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
$86.50
Low target
$60.00
High target
$113.00
Barclays
Maintains
Equal-Weight
$60.00
10 Aug 22
SVB Leerink
Maintains
Outperform
$113.00
10 Aug 22

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

9 Aug 22
30 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 278.37M 278.37M 278.37M 278.37M 278.37M 278.37M
Cash burn (monthly) 10.4M (no burn) 27.32M 24.28M 17.43M (no burn)
Cash used (since last report) 31.43M n/a 82.58M 73.37M 52.67M n/a
Cash remaining 246.94M n/a 195.79M 205M 225.7M n/a
Runway (months of cash) 23.7 n/a 7.2 8.4 13.0 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
6 Sep 22 FMR Common Stock Sell Dispose S Yes No 54.25 551 29.89K 0
6 Sep 22 FMR Common Stock Other Acquire J Yes No 0 551 0 551
6 Sep 22 FMR Common Stock Other Dispose J Yes No 0 25,620 0 0
1 Sep 22 John Maraganore Stock Option Common Stock Grant Acquire A No No 55.58 10,391 577.53K 10,391
1 Sep 22 Cooper Graham K Stock Option Common Stock Grant Acquire A No No 55.58 10,391 577.53K 10,391
1 Sep 22 Ho Carole Stock Option Common Stock Grant Acquire A No No 55.58 10,391 577.53K 10,391
1 Sep 22 Burow Kristina Stock Option Common Stock Grant Acquire A No No 55.58 10,391 577.53K 10,391
84.8% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 200 237 -15.6%
Opened positions 26 49 -46.9%
Closed positions 63 42 +50.0%
Increased positions 90 93 -3.2%
Reduced positions 43 44 -2.3%
13F shares Current Prev Q Change
Total value 2.05B 2.8B -26.6%
Total shares 59.68M 54.36M +9.8%
Total puts 242.8K 388.3K -37.5%
Total calls 248K 327.3K -24.2%
Total put/call ratio 1.0 1.2 -17.5%
Largest owners Shares Value Change
ARK Investment Management 8.79M $309.31M +7.2%
ARCH Venture Fund IX 5.84M $0 0.0%
Vanguard 5.25M $203.09M +11.3%
BLK Blackrock 5.16M $199.57M +27.7%
FMR 4.8M $185.81M -11.4%
Temasek 3.96M $153.26M 0.0%
Farallon Capital Management 3.47M $134.41M +33.8%
STT State Street 3.34M $129.15M +68.4%
MWG Management 2.35M $90.85M 0.0%
Redmile 1.85M $71.61M +0.8%
Largest transactions Shares Bought/sold Change
STT State Street 3.34M +1.35M +68.4%
BLK Blackrock 5.16M +1.12M +27.7%
Farallon Capital Management 3.47M +877.88K +33.8%
Victory Capital Management 21.58K -663.61K -96.9%
FMR 4.8M -615K -11.4%
ARK Investment Management 8.79M +591.32K +7.2%
Vanguard 5.25M +534.49K +11.3%
Deep Track Capital 1.25M +486.25K +63.7%
Casdin Capital 375K -443.82K -54.2%
Yiheng Capital Management 363.8K +340.4K +1454.7%

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: breached, called, constructed, Construction, deceptive, dispute, employer, enriched, ESCAPE, Evasion, fail, hearing, highlighting, inadvertently, individual, inflow, Kingdom, marketplace, moving, newly, noncancelable, official, outflow, perception, scheduled, secret, settlement, substance, unfair, unjustly, variance, vigorously, wrongfully, Zealand
Removed: escalation, FASB, noted, percent, transfer